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PANEL DISCUSSION
MR. MISROCK: Now I'd like to throw the session open for
questions from the audience.
AUDIENCE MEMBER*: I have two questions, one for Mr.
Montalto and one for Hal Wegner. Mr. Montalto, I wonder, is no
thought being given in the trademark Directive considerations to
the protection of unregistered product designs-product configura-
tions that would be out there and may claim secondary meaning,
or inherent distinct difference, or whatever? I see no traces of it.
I thought I heard some mention that you had better register every-
thing or you're going to be in trouble. I want to know if you are
just going to leave that out there in the cold?
And for Mr. Wegner, I think you strongly support the first-to-
file system. I just want to know, do you also support the publica-
tion of all applications including failed applications; and, if you do
support it, would you still support it if Professor Fryer's view were
correct, that the initial application has to have some genuine con-
tent to it?
MR. MONTALTO: If I understood your question, you were
talking about two different points. One involved what is about to
be signed regarding protection under Community law in respect to
the trademark law; and the second one involved unregistered prod-
ucts or signs which in many cases aren't being protected.
First of all, about the signs, as you know, we are providing for
that lack in the Regulation. That would be in the talks that will be
made by my colleagues, that the Community really is doing what
it can to give protection also for these items and subjects.
For your second question about non-registered trademarks,
Community law in the Directive leaves to the Member States the
possibility that these rights can be recognized under the law. We
give also important value to a well-known mark, that is a mark that
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is recognized and is very famous. If it is not registered, it can be
used and the Member State can also be in a position to ask the
user-owner also for validation of a later trademark that is registered
if their trademark has been used and is very well-known around the
states or the Community.
PROFESSOR WEGNER: I think that Professor Reichman
raised a very good point, as also did Professor Fryer.
Let's start with the provisional application. It is absolutely true
that an attorney should be involved with the first filing, and it is
absolutely true that the first filing has to have a disclosure of the
proper scope of protection. Professor Beier, Dr. Rainer Moufang,
both of Max Planck, and I have each written on this problem in the
Max Planck journal LL C. in great detail, ad infinitum, ad nauseam,
about this problem. It is a serious problem and must be addressed.
The real reason why Americans file slowly, why our application
procedure with attorneys is so expensive, is not because of this
question. The inventor gives you working examples disclosure and
the best prior work in the field, and the attorney can fairly eyeball,
and make a good calculated guess about the scope of protection.
He can have multiple scope definitions and throw away the scopes
he doesn't like later on and he has protection as of that date.
The real problem is the in terrorem effect of patent fraud. If
you look at the last double issue of the AIPLA Quarterly Journal,1
we revisited this problem again in 1992. It's my feeling that when
a U.S. attorney gets a patent application, it's not the problem of
defining the invention; it's all the ancillary bells and whistles, and
the fact that if the patent is ever granted and goes into litigation,
there is an eighty-to-ninety percent chance that that attorney will
be charged with fraud.
This in terrorem effect must be eliminated. So it is part of the
proposal we have, and I have outlined a legislative proposal for
this, to get rid of patent fraud. That's what we need to do, and
then we have a disclosure document.
1. Harold C. Wegner, Patent Simplification Sans Patent Fraud, 20 AIPLA Q.J. 211,
214-16 (1992).
1993]
350 FORDHAM INTELL. PROP., MEDIA & ENT. L.J.
Now, even without that, why do I want a disclosure document?
Well, I think it's important that investors be told about the prob-
lems of scope, that they need to choose a turning wherever possi-
ble. But I want the inventor to have the option of this disclosure
document. Professor Irving Kayton has done studies which show
that Japanese routinely file their patent applications five to ten
months earlier than Americans do.
So imagine that you have all the biotechnologists of importance
going to a conference in Cologne or Kyoto or California, anywhere
in the world, and they see a new development and they rush home
to their laboratories and say, "Where can I go from here?" If each
of the inventors goes back to his laboratory at home-one in Kyo-
to, one in California, one in Cologne-and they each, about the
same time, come up with the same innovation, unless the American
is five or ten months earlier, he loses the race to the patent office.
Isn't that an atrocity?
I want to encourage early filings. I want first-to-file to force
early filings. And let's make no mistake about it, we kid ourselves
when we say that the individual inventor is going to win a patent
interference. Thirty times a year the individual inventor, or any
inventor, who is second to file wins a patent interference-thirty
times a year out of filings of 160,000 patent applications. Not only
does he have a very, very poor chance of getting a patent in the
United States, he absolutely will not get a patent in the rest of the
world because the rest of the world today is under first-to-file.
Well, why don't we get the rest of the world to change to our
system? That's ludicrous, but I've heard people make that propos-
al. We should now re-think things. Canada had our system until
1987, when they changed their law, effective 1989, and unilaterally
went to this. 2
Now, with regard to Professor Reichman's question about pub-
lication, yes, I want publication at eighteen months of every patent
application. I want the inventors to diligently pursue their technol-
ogy. What I don't want are "submarine patents," where inventors
2. The Patent Act, R.S.C. 1970, ch. P-4; The Patent Rules, C.R.C. 1978, ch. 1250.
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have a little idea, don't do a thing with it, but leave it there until
somebody else develops the technology, and then patents it. To-
day's example is Jerry Lemelson, who, through whatever means,
lets patent applications sit for twenty years, files only in the United
States, and then after twenty years, after the technology is devel-
oped, sues everybody. Why don't we learn these lessons?
The classic example was George Selden. George Selden, in
1879, before Henry Ford, before Daimler Benz, before the gas cars,
wrote a patent application and claimed gas cars-1879. For sixteen
years he let that sit. Along the way, as Henry Ford came along, as
Daimler Benz came along, as everybody else came along, he modi-
fied his application to mirror their advances. It was pending from
1879 to 1895; 1895, he got his patent. He held up the industry.
He had a patent tax on most of the industry. It was not until 1911
that the Second Circuit found a quirk to find noninfringement, and
then the patent was about to expire. We don't need George
Seldens; we don't need Lemelsons.
If an inventor is working in his garage, I want him to get for-
eign protection. As a matter of public policy, here you've had
Reagan, Bush, Clinton, back to Kantor, back to Emery Simon,
saying, "We need foreign intellectual property rights." Let's en-
courage the American inventor to file abroad and get those rights
in Japan and Europe, and file within twelve months. There will
then be automatic publication at eighteen months. I want every
pressure put on the inventor to file abroad.
Now, they say, "It is cheap to file in the United States, expen-
sive abroad." Well, I want the inventor to get financing to license.
AUDIENCE MEMBER: Can you explain how that interrelates
with what I've heard about the grace period being retained? Is it
going to be retained? Will that lead to harmonization? And, if it
isn't retained, does that help Americans file abroad?
PROFESSOR WEGNER: The grace period is apples and or-
anges to the publication. There is no necessary correlation between
a grace period and first inventor, first-to-file. Germany had a grace
period, and they lost it as part of the European Patent Convention.
In fact, the harmonization discussions started not because of Dr.
1993]
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Bogsch, not because of people in the United States, but because
Heinz Bardehle and his colleagues in Germany were using that as
a guise to reinstate a grace period in Germany.
There is no relation between the two. I personally think a
grace period in foreign countries would be very beneficial, without
any down-side risks. In the big companies, a grace period is not
important for inventions that are done in-house, because a big com-
pany has security and they tell their inventors, "Don't you dare
publish."
The problem occurs when somebody at Berkeley or somebody
at MIT who is patent-naive and thinks of himself as a scientist-he
doesn't even know that he's made an invention; he's made a dis-
covery which he has published in the journal of this and that, and
all of a sudden, the very next week, a scientist from a Merck or a
Pfizer comes and says, "You've made a wonderful invention. We
want to commercialize your invention and we want to take over
your patent." "Patent? I don't have a patent." So, for that situa-
tion, a grace period is very, very important; otherwise, we can't
commercialize these inventions and we can't get foreign rights.
MR. MISROCK: First of all, with respect to your suggestion
that we eliminate fraud and misconduct in the U.S. Patent Office,
I am unequivocally opposed to that as a trial lawyer. I have been
in eight cases where we had found and proved by fairly convincing
evidence misconduct in the Patent Office. In many cases there is
no smoking gun; you drag it out of them. I do not want to see
games played in the Patent Office that used to be played in the
1940s and 1950s. So I think that Damocles' Sword serves a
healthy function hanging over the head of patent solicitors.
Let me ask two questions to both Hal and Mr. Montalto. First,
the substantive one: years ago-not so long ago-I was in a case
in the International Trade Commission ("ITC") called In re Certain
Doxorubicin Products.3 This particular chemotherapeutic agent is
called Adriamycin by its trade name. It was a U.S. patent owned
by Farmitalia Carlo Erba which was based upon an Italian priority
3. 20 U.S.P.Q.2d (BNA) 1602 (I.T.C. 1990).
[Vol. 4:299
DEVELOPMENTS IN PATENT AND TRADEMARK
case for a method of making this particular pharmaceutical. In
those days in Italy, you could not get a patent on a process for
making a pharmaceutical; it was banned under the Italian law.
Now, we noticed that the Italian application was filed, the U.S.
counterpart was then filed, and then the Italian was immediately
abandoned because as a matter of law it didn't meet the require-
ments.
We had good defenses in that case-we had a Ruscetta Jenny
defense4 and we had sections 102 and 103 defenses. But, it struck
me that-I did not want to use the ITC as a forum to do this, and
I certainly don't want to ever use the Patent Office as a forum to
do it-there was not compliance with section 119. How can you
possibly have the requirements met of duly filed application for
U.S. counterpart, under section 119 of the Patent Act, if as a matter
of law you cannot get a patent within that particular country?
Now, this becomes important particularly in pharmaceutical use
cases. These are very important in the United States. Even though
the use claim may be infringed by the patient or infringed by the
doctor, no one is going to sue a patient or a doctor; but you cer-
tainly can sue the supplier of the drug because the patient package
insert can give rise to a section 271(b) inducement of infringement
cause of action.
So the question to both of you is: What does "duly filed"
mean when as a matter of law, whether it's a European patent or
otherwise, you cannot get patent coverage within that jurisdiction?
MR. MONTALTO: The law in Italy has been changed.
MR. MISROCK: Yes, you did change the law in Italy. But I
was talking about-
MR. MONTALTO: Before it was not possible to obtain a pat-
ent. What you said for medicinal products, for pharmaceutical
products, in Italy it was not possible to obtain a patent. But now
the legislation is changed and now it is completely equal as to the
other products. So this case, as you related it, cannot happen in Italy.
4. See In re Ruscetta, 255 F.2d 687 (C.C.P.A. 1958).
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MR. MISROCK: Well, let's suppose you are precluded in Eu-
ropean patents from getting coverage on method of treatment, as
you are today. There are potential ways around it and they have
compositions, even though the compound is old, directed to that
particular disease. But let's suppose for the sake of argument that
you cannot get coverage on method of treatment. One of the most
important cases now being litigated is a method for the treatment
of HIV-I for AIDS patients which comprises administering Agent
T; it's a method claim in the United States, originally filed in Brit-
ain. How can that be duly filed under the foreign law when as a
matter of law you cannot get coverage in that case in England or,
in many cases, under the European patent? Why should it be rec-
ognized as a foreign priority document in the United States merely
because you use manipulative steps: first, filing a foreign case first
to get the date when, as a matter of law, you cannot get the patent,
and, second, coming over here, abandoning the European, and con-
tinuing to prosecute the American? I do not know whether there
is an answer to my question, but I'll ask it anyway.
AUDIENCE MEMBER: Could I not just make a brief com-
ment on that issue? My studies of the last provision of the Paris
Convention back in Lisbon in 1958 was that it addressed the issue
of abandonment of the originally filed application because of cir-
cumstances such as those you are postulating. It was written in the
Convention at that point that even if the original filing application
was abandoned, you could still form that basis under the Conven-
tion.
MR. MISROCK: But I've gone further than just abandonment.
I'm going to the point where there is no legal basis for getting
patent coverage in that country.
PROFESSOR WEGNER: The answer is Article 4H of the
Paris Convention. You can have many different inventions dis-
closed in an individual patent application-some patentable, some
unpatentable; some patentable under one law, some unpatentable
under another law. But, as long as the invention is disclosed, as
* John Richards, Partner, Ladas & Parry, New York, N.Y.
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long as the application documents in the original country disclose
the invention, that is the basis for priority to a claim to that inven-
tion in the Convention country. That is explicitly clear under Arti-
cle 4H of the Paris Convention.
As to a regular national filing, the home country determines
whether it gives a serial number and filing date to the case. If it
does that, it's a regular national filing judged under the home coun-
try's law, not under the Convention country law.

